Laboratory Monitoring of Treatment of Patients With Obesity and Type 2 Diabetes Mellitus

Abstract

One of the factors in the development of obesity is impaired sensitivity to leptin (leptin resistance). Adiponectin is a protein produced in adipocytes, counteracts the formation of metabolic syndrome, increases the sensitivity of hepatocytes and muscle tissue to insulin, and has a protective effect on the vascular wall. However, as soon as adipose tissue increases in volume, the concentration of adiponectin decreases. Adiponectin was discovered only a few years ago and immediately attracted genuine interest, as evidenced by the fierce competition between pharmaceutical companies, which immediately began developing drugs based on this hormone. Preliminary results indicate the possibility of using a test for determining the concentration of adiponectin in the blood serum for the diagnosis and prognosis of the metabolic syndrome, as well as for monitoring drugs based on adiponectin. For many years, the main pathogenetic theory of atherosclerosis and coronary heart disease development was the theory of hyperlipoproteinemia. It is known that the relationships between obesity, insulin resistance, leptin resistance, hypoadiponectemia, systemic inflammation, lipid metabolism disorders and atherosclerosis are more complex and require additional research. The importance of timely detection of metabolic syndrome and its complications determines the relevance of conducting research to improve diagnostic methods and evaluate the treatment of patients with obesity and type 2 diabetes. The introduction of new tests in laboratory monitoring of the effectiveness of various treatment regimens for patients with obesity and type 2 diabetes seems relevant. The objective of this study is to evaluate the role of laboratory monitoring in assessing treatment effectiveness and safety among patients with obesity and type 2 diabetes mellitus